

Synthesis of Oxazoles by Tandem Cycloisomerization/Allylic Alkylation of Propargyl Amides with Allylic Alcohols: $\text{Zn}(\text{OTf})_2$ as π Acid and σ Acid Catalyst

Bin Wang,[†] Ying Chen,[†] Ling Zhou,[‡] Jianwu Wang,^{*,†} Chen-Ho Tung,[†] and Zhenghu Xu^{*,†,§}


[†]Key Lab of Colloid and Interface Chemistry of Ministry of Education, School of Chemistry and Chemical Engineering, Shandong University, No. 27 South Shanda Road, Jinan, Shandong 250100, China

[§]State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, P. R. China

[‡]Department of Chemistry and Biochemistry, Miami University, Oxford, Ohio 45056, United States


Supporting Information

ABSTRACT: A $\text{Zn}(\text{OTf})_2$ -catalyzed tandem cycloisomerization/allylic alkylation of *N*-(propargyl)arylamides and allylic alcohols to produce oxazole derivatives has been successfully developed. The zinc catalyst served as π acid and also σ acid in this reaction. The target allylic oxazoles have been transformed into multisubstituted diene structures, which are potential aggregation-induced emission active optical materials.



Oxazole derivatives are privileged five-membered heterocycles widely presented in a variety of natural products and pharmaceuticals with significant biological activities.¹ Oxazoles are useful synthetic intermediates in organic synthesis and also important ligands for transition-metal catalysis.² Thus, the development of a practical and useful method to access this heterocycle is of great importance. Recently, propargylic amides have been well studied as versatile building blocks to prepare oxazoles.³ Various transition-metal catalysts could catalyze these transformations, and significant progress has been made in this area (Scheme 1). For example, a

Scheme 1. Transition-Metal-Catalyzed Cyclization/Functionalization of Propargylic Amides To Synthesize Oxazoles




$\text{Pd}(0)$ -catalyzed coupling/cyclization of propargylic amide **1** with ArI has been developed to synthesize disubstituted oxazoles in 2001.⁴ Later in 2010, Hashmi and co-workers

developed a gold(III)-catalyzed cyclization of propargylic amide **1** to access methyl oxazoles.⁵ Very recently, Shi and Jiao developed a synergistic gold(I)/Fe(III) dual catalysis from propargylic amide to oxazole aldehyde.⁶ We report here a cheap metal $\text{Zn}(\text{OTf})_2$ -catalyzed cyclization/allylic alkylation cascade reaction of propargylic amides with allylic alcohol **2** to prepare oxazole derivatives. In this transformation, elimination of one molecule of water is the only byproduct. More importantly, $\text{Zn}(\text{OTf})_2$ acted as a π acid to catalyze the cyclization of propargylic amide, but also served as a σ acid to activate the allylic alcohol, which is the most important feature of this work.

Previously we combined Au as the π acid and another early transition metal as the σ acid and developed a series of bimetallic relay catalysis to access various biologically important fused or spiro aminals.⁷ Following this chemistry, π acids such as gold(I) catalysts or Zn(II) catalysts could catalyze the cyclization of **1a** to form an exocyclic double bond intermediate M^1 , which could act as a nucleophile to participate in another asymmetric allylic alkylation⁸ in the presence of a palladium catalyst and chiral phosphine ligands to build chiral oxazole derivatives (Scheme 2). To our great surprise, whatever chiral ligands such as Trost's ligand or SEGPHOS were used, the coupled products **3a** were all racemic (eq 1). These results indicated that the chiral palladium catalyst might not participate in this reaction. Then the chiral palladium catalysts were removed from the reaction system, and the product **3a** was isolated in similar yield (eq 2). Herein the zinc catalyst not only served as π acid to catalyze the cyclization of propargylic amide but also acted as σ acid to activate the allylic carbonate

Received: October 14, 2015

Published: November 30, 2015

Scheme 2. Unexpected Zn(OTf)₂-catalyzed cycloisomerization/allylic alkylation cascade to synthesize oxazoles


Allylic alkylation was usually catalyzed by precious metal catalysts such as Pd and Ir, but in comparison zinc salts⁹ are cheap and readily available; we thereby decided to study this reaction in detail. Compared with allylic carbonates or acetates, such reactions of allylic alcohols¹⁰ are more atom-economic considering water as the only byproduct, and the whole synthetic process is shorter because allylic carbonates are synthesized from the corresponding alcohols.¹¹ However, because the hydroxyl group is not a good leaving group, moreover, the in situ formed intermediate **M**¹ is very easy to isomerize into methyl oxazole **5a** in the presence of Brønsted acid or Lewis acid, such a reaction is very challenging.

To test this hypothesis, propargylic amide **1a** and allylic alcohol **2a** were subjected to this reaction in the presence of zinc triflate. To our delight, the target product **3a** could be isolated in 76% yield (entry 1, Table 1). Inspired by the observed results, we continued to optimize the reaction conditions. It turned out that other Lewis acids such as In(OTf)₃ and


Table 1. Optimization of Reaction Conditions^a

entry	catalyst	1a:2a	solvent	T/°C	yield % ^b
1	Zn(OTf) ₂	2:1	DCE	60	76
2	In(OTf) ₃	2:1	DCE	60	56
3	Cu(OTf) ₂	2:1	DCE	60	23
4 ^c	Ph ₃ PAuNTf ₂	2:1	DCE	60	58
5	FeCl ₃	2:1	DCE	60	<10
6	ZnI ₂	2:1	DCE	60	<10
7	ZnCl ₂	2:1	DCE	60	21
8	Zn(OTf) ₂	1.5:1	Toluene	60	24
9	Zn(OTf) ₂	1.5:1	CH ₃ CN	60	<5
10	Zn(OTf) ₂	1.5:1	THF	60	<5
11	Zn(OTf) ₂	1.5:1	DCE	50	59
12	Zn(OTf) ₂	1.5:1	DCE	70	93
13 ^d	Zn(OTf) ₂	1.5:1	DCE	70	93
14 ^e	Zn(OTf) ₂	1.5:1	DCE	70	85
15	HOTf	1.5:1	DCE	70	0

^aReaction conditions: **2a** (0.1 mmol), Lewis acid (10 mol %), 4 Å molecular sieves (50 mg), C_{2a} = 0.05 M, 13 h. ^bIsolated yield. ^c5 mol % of catalyst. ^dC_{2a} = 0.1 M. ^e5 mol % of catalyst, C_{2a} = 0.1 M.


Ph₃PAuNTf₂ could also generate product **3a** in less than 60% yields (entries 2–5). The reaction of FeCl₃ could not produce the coupled product **3a**, but only the isomerized methyl oxazole **5a**. Solvent screening showed that DCE is the optimal solvent (entries 8–11). The desired product could be isolated in 93% yield by raising the temperature to 70 °C (entry 12). In addition, the use of protic acid HOTf instead of Zn(OTf)₂ could not afford any product.

With the optimized conditions established, the scope of various propargylic amides was examined at first. As summarized in Table 2, a large variety of disubstituted or trisubstituted

Table 2. Substrate Scope of the Propargylic Amides^a



^aReaction conditions: **1** (0.3 mmol), **2a** (0.2 mmol), Zn(OTf)₂ (10 mol %), 4 Å molecular sieves (65 mg), C_{2a} = 0.1 M, 70 °C, 13 h, isolated yields were reported.

oxazole derivatives were synthesized in good to excellent yields with very wide scope. For the para-substituted substrates, the reaction afforded the desired products in good yields (**3b–g**), independent of electron-withdrawing or electron-donating groups. A series of functional groups such as fluoro, bromo, methoxy, trifluoromethyl, and cyano were well tolerated under this reaction condition. Substituents at the *meta* or *ortho* position did not affect this reaction, giving the corresponding

Table 3. Substrate Scope of Allylic Alcohols^a

^aReaction conditions: **1a** (0.3 mmol), **2** (0.2 mmol), $\text{Zn}(\text{OTf})_2$ (10 mol %), 4 Å molecular sieves (65 mg), $C_{2a} = 0.1$ M, 70 °C, 13 h, isolated yields were reported. ^bAt 60 °C.

Scheme 3. Control Experiments and Proposed Reaction Mechanism



oxazoles in very good yields (**3h–j**). Substrates bearing a thienyl or styryl group were all suitable substrates for this transformation and gave the corresponding oxazoles in 75%

and 53% yields (**3k**, **3l**). In addition, adding one more substituent at the propargylic position could generate fully substituted oxazole derivatives smoothly (**3m**, **3n**).

Next, the scope of allylic alcohols was investigated (Table 3). Various symmetric diaryl allylic alcohols were suitable substrates for this transformation, giving the corresponding products in 50–68% yields (3o–3q). *gem*-Diphenyl alcohols 2' also reacted smoothly and gave the corresponding functionalized oxazoles in moderate to good yields (3s–3w). When asymmetric allylic alcohol 2r was used in this reaction, equal amounts of two regioisomers were obtained (3r/3r' = 1/1), which in principle suggested that both S_N2 and S_N2' mechanisms were involved in this reaction. Unfortunately, other alcohols such as cinnamyl alcohol and diphenylcarbinol did not react in this transformation. These results may help to understand the reaction mechanism.

To better understand the reaction process, control experiments were conducted. A nonracemic allylic alcohol 2a-ent (60% ee) was prepared by CBS reduction of chalcone. When this chiral alcohol 2a-ent was subjected to the standard reaction, racemic product 3a was obtained (eq 3, Scheme 3), which suggested a possible allylcarbenium ion mechanism. The reaction of 1a in the presence of Zn(OTf)₂ could form oxazoline M¹ in 70% yield. The isolated M¹ was subjected to standard reaction with alcohol 2a, and the product 3a was isolated in 88% yield (eq 4, Scheme 3).

A plausible mechanism was proposed in Scheme 3. First, Zn(OTf)₂ acted as π acid to activate the triple bond of 1a and subsequent intramolecular *S*-*exo*-*dig* cyclization forming the oxazoline intermediate M¹. At the same time, the zinc catalyst coordinated with the hydroxyl group and double bond of alcohol 2a to form a relatively stable allylcarbenium ion intermediate M⁴.¹² The intermolecular ene type reaction between nucleophilic M¹ and electrophilic M⁴ produced the aromatic oxazole derivatives. At the same time, the released proton and [Zn(OTf)₂OH]⁻ reacted together to regenerate the zinc catalyst. Thus, the S_N1 type reaction mechanism led to the racemic product when chiral 2a was used.

The obtained allylic oxazoles belong to a unique type of structure, which is difficult to access by other methods. These compounds could be oxidized to conjugated dienes 4 in the presence of catalytic amounts of Yb(OTf)₃ and 1 equiv of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) at room temperature (eq 5, Scheme 3).¹³ Both an electron-donating group and an electron-withdrawing group were tolerated and gave functionalized dienes in respectable yields (4c, 4f). The structure of 4f was unambiguously characterized by single X-ray crystallography (for details, see Supporting Information).¹⁴ These products all are large conjugated functionalized molecules and might have peculiar photophysical characteristics. The UV/vis absorption and emission spectra of the dienes 4a, 4c, and 4f in solution were characterized and are shown in Figure 1 (left). They displayed maximum absorption peak around 370 nm, and exhibited blue emission around 450 nm.

Tetrasubstituted or trisubstituted olefins may have an extraordinary photophysical phenomenon of aggregation-induced emission (AIE) that is nonemissive or low-emissive in solution, but induced to emit efficiently by aggregate formation in the solid state.¹⁵ It is very interesting that the obtained dienes are also AIE active molecules. As illustrated in Figure 1 (right), when the water fraction increased to 90%, the fluorescence intensity greatly increased relative to its pure THF solution. As water was a poor solvent for 4a, increasing the vol % of water in the mix solvent of THF/H₂O induced aggregation of 4a. These functionalized molecules are very promising as blue emissive materials such as organic light-emitting diodes (OLED).




Figure 1. UV/vis absorption and fluorescence spectra of 4a, 4c, and 4f in dilute dichloromethane solution (left). Emission spectra of 4a in THF/H₂O solvent mixtures with different volume percents of H₂O (right). Concentration of 10⁻⁵ M.

In conclusion, we have developed a zinc-catalyzed cyclization/allylic alkylation cascade reaction as a convenient synthetic method toward functionalized oxazoles. The zinc catalyst acted as a π acid to activate *N*-(propargyl)arylamides, but also served as σ acid to facilitate C–O bond cleavage of allylic alcohols to form an allylcarbenium ion, which is the most important feature of this reaction. The allylic oxazoles were easily transformed into large π-conjugated dienes, which proved to be good AIE luminogens and will potentially have more applications as the AIE active materials.

EXPERIMENTAL SECTION

General Details. All NMR spectra were recorded on a 400 MHz spectrometer. High-resolution mass spectrometry (HRMS) was measured in positive-ion mode on a Q-TOF instrument with an ESI ion source. Routine monitoring of the reaction was performed by TLC using precoated silica gel plates. All the reagents and solvents used in this reaction such as DCE were purchased from a local company and used directly. Allylic alcohols 2s–2w were prepared by a reported procedure.¹⁶

General Procedure for the Synthesis of Compounds 3. 2 (0.2 mmol, 0.1 mol/L), 1 (0.30 mmol), Zn(OTf)₂ (10 mol %), and 4 Å molecular sieves were mixed in 2 mL of DCE. The mixture was kept stirring at 70 °C for 13 h. After the reaction was completed (monitored by TLC), the solution was filtered on Celite and then evaporated under reduced pressure. Purification by flash column chromatography afforded the desired product 3.

(*E*)-5-(2,4-Diphenylbut-3-en-1-yl)-2-phenyloxazole (3a): yellow oil (65.3 mg, 93%, petroleum ether/EtOAc = 15/1); ¹H NMR (400 MHz, CDCl₃) δ 7.98–7.90 (m, 2H), 7.45–7.15 (m, 13H), 6.75 (s, 1H), 6.42 (d, *J* = 3.1 Hz, 2H), 3.91 (ddd, *J* = 10.4, 7.2, 2.9 Hz, 1H), 3.30–3.15 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 160.8, 150.7, 142.8, 137.1, 132.2, 130.7, 130.0, 128.8, 128.7, 128.6, 127.7, 127.6, 127.4, 126.9, 126.309, 126.1, 125.2, 47.7, 32.5; IR (neat) ν (cm⁻¹) 3057, 3025, 1594, 1548, 1489, 1448, 1353, 1264, 1120, 1064, 1025, 962, 826, 773, 734, 709, 688, 547, 525, 491; HRMS exact mass calcd for (C₂₅H₂₁NO + H) requires *m/z* 352.1701, found *m/z* 352.1696.

(*E*)-5-(2,4-Diphenylbut-3-en-1-yl)-2-(*p*-tolyl)oxazole (3b): yellow oil (62.4 mg, 85%, petroleum ether/EtOAc = 15/1); ¹H NMR (400 MHz, CDCl₃) δ 7.83 (d, *J* = 8.0 Hz, 2H), 7.36–7.13 (m, 12H), 6.72 (s, 1H), 6.41 (d, *J* = 2.9 Hz, 2H), 3.94–3.83 (m, 1H), 3.27–3.13 (m, 2H), 2.35 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 161.1, 150.4, 142.9, 140.2, 137.2, 132.3, 130.7, 129.5, 128.8, 128.6, 127.7, 127.4, 126.9, 126.3, 126.1, 125.12, 125.09, 47.7, 32.5, 21.5; IR (neat) ν (cm⁻¹) 3057, 3023, 2918, 1723, 1679, 1599, 1553, 1497, 1451, 1256, 1178, 1113, 1067, 965, 824, 729, 695, 505; HRMS exact mass calcd for (C₂₆H₂₃NO + H) requires *m/z* 366.1858, found *m/z* 366.1864.

(*E*)-5-(2,4-Diphenylbut-3-en-1-yl)-2-(4-methoxyphenyl)oxazole (3c): yellow oil (63.6 mg, 83%, petroleum ether/EtOAc = 10/1); ¹H NMR (400 MHz, CDCl₃) δ 7.87 (d, *J* = 8.8 Hz, 2H), 7.38–7.13 (m, 10H), 6.92 (d, *J* = 8.8 Hz, 2H), 6.70 (s, 1H), 6.45–6.37 (m, 2H), 3.89 (dd, *J* = 6.8, 3.3 Hz, 1H), 3.81 (s, 3H), 3.28–3.13 (m, 2H);

^{13}C NMR (100 MHz, CDCl_3) δ 161.1, 160.9, 150.1, 142.9, 137.1, 132.3, 130.6, 128.7, 128.6, 127.69, 127.66, 127.4, 126.8, 126.3, 125.0, 120.7, 114.2, 55.4, 47.7, 32.5; IR (neat) ν (cm^{-1}) 3059, 3023, 2836, 1611, 1494, 1451, 1358, 1302, 1249, 1169, 1120, 1103, 1025, 962, 833, 739, 692, 610, 522; HRMS exact mass calcd for ($\text{C}_{26}\text{H}_{23}\text{NO}_2 + \text{H}$) requires m/z 382.1807, found m/z 382.1807.

(*E*)-5-(2,4-Diphenylbut-3-en-1-yl)-2-(4-fluorophenyl)oxazole (**3d**): yellow oil (61.4 mg, 83%, petroleum ether/EtOAc = 15/1); ^1H NMR (400 MHz, CDCl_3) δ 7.99–7.78 (m, 2H), 7.37–7.13 (m, 10H), 7.11–7.01 (m, 2H), 6.73 (s, 1H), 6.42 (d, $J = 3.2$ Hz, 2H), 3.96–3.79 (m, 1H), 3.32–3.06 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.8 (d, $^1J_{\text{C-F}} = 248.0$ Hz), 160.0, 150.8, 142.8, 137.1, 132.2, 130.7, 128.8, 128.6, 128.1 (d, $^3J_{\text{C-F}} = 9.0$ Hz), 127.6, 127.5, 126.9, 126.3, 125.2, 124.1 (d, $^4J_{\text{C-F}} = 3.0$ Hz), 115.9 (d, $^2J_{\text{C-F}} = 22.0$ Hz), 47.8, 32.4; IR (neat) ν (cm^{-1}) 3059, 3025, 2916, 1730, 1604, 1558, 1494, 1451, 1412, 1232, 1152, 1123, 1091, 962, 838, 736, 692, 605, 518; HRMS exact mass calcd for ($\text{C}_{25}\text{H}_{20}\text{FNO} + \text{H}$) requires m/z 370.1607, found m/z 370.1607.

(*E*)-2-(4-Bromophenyl)-5-(2,4-diphenylbut-3-en-1-yl)oxazole (**3e**): yellow oil (77.0 mg, 89%, petroleum ether/EtOAc = 15/1); ^1H NMR (400 MHz, CDCl_3) δ 7.77 (d, $J = 8.4$ Hz, 2H), 7.52 (d, $J = 8.4$ Hz, 2H), 7.39–7.13 (m, 10H), 6.75 (s, 1H), 6.41 (d, $J = 2.6$ Hz, 2H), 3.88 (dd, $J = 6.7, 3.5$ Hz, 1H), 3.29–3.11 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 160.0, 151.1, 142.7, 137.1, 132.1, 132.0, 130.7, 128.8, 128.6, 127.6, 127.53, 127.51, 126.9, 126.6, 126.3, 125.4, 124.4, 47.7, 32.5; IR (neat) ν (cm^{-1}) 3057, 3023, 2917, 1724, 1679, 1590, 1553, 1497, 1451, 1256, 1178, 1113, 1067, 965, 827, 729, 695; HRMS exact mass calcd for ($\text{C}_{25}\text{H}_{20}\text{BrNO} + \text{H}$) requires m/z 430.0807, found m/z 430.0801.

(*E*)-5-(2,4-Diphenylbut-3-en-1-yl)-2-(4-(trifluoromethyl)phenyl)oxazole (**3f**): yellow oil (75.7 mg, 90%, petroleum ether/EtOAc = 15/1); ^1H NMR (400 MHz, CDCl_3) δ 8.02 (d, $J = 8.2$ Hz, 2H), 7.65 (d, $J = 8.3$ Hz, 2H), 7.40–7.15 (m, 10H), 6.80 (s, 1H), 6.45–6.39 (m, 2H), 3.91 (ddd, $J = 10.6, 7.2, 3.4$ Hz, 1H), 3.32–3.18 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.4, 151.7, 142.6, 137.0, 132.0, 131.7, 131.4, 130.8, 129.7, 128.8, 128.6, 127.6, 127.5, 127.0, 126.3, 126.2, 126.0, 125.8, 125.8, 125.7, 125.3, 122.6, 47.8, 32.4; IR (neat) ν (cm^{-1}) 3059, 3029, 2921, 1732, 1605, 1558, 1494, 1451, 1418, 1153, 1123, 1091, 972, 838, 737, 692, 609; HRMS exact mass calcd for ($\text{C}_{26}\text{H}_{20}\text{F}_3\text{NO} + \text{H}$) requires m/z 420.1575, found m/z 420.1578.

(*E*)-4-(5-(2,4-Diphenylbut-3-en-1-yl)oxazol-2-yl)benzonitrile (**3g**): yellow solid (37.5 mg, 50%, petroleum ether/EtOAc = 10/1); mp 104–106 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.00 (d, $J = 8.4$ Hz, 2H), 7.68 (d, $J = 8.4$ Hz, 2H), 7.41–7.15 (m, 10H), 6.83 (s, 1H), 6.45–6.38 (m, 2H), 3.90 (ddd, $J = 9.5, 7.2, 3.0$ Hz, 1H), 3.32–3.18 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 158.9, 152.2, 142.5, 136.9, 132.6, 131.9, 131.4, 130.8, 128.8, 128.6, 127.6, 127.0, 126.4, 126.28, 126.27, 126.0, 118.5, 113.2, 47.8, 32.4; IR (neat) ν (cm^{-1}) 3059, 3025, 2923, 2221, 1594, 1489, 1448, 984, 972, 836, 756, 741, 690, 651, 549, 486; HRMS exact mass calcd for ($\text{C}_{26}\text{H}_{20}\text{N}_2\text{O} + \text{H}$) requires m/z 377.1654, found m/z 377.1652.

(*E*)-5-(2,4-Diphenylbut-3-en-1-yl)-2-(*o*-tolyl)oxazole (**3h**): yellow oil (68.6 mg, 94%, petroleum ether/EtOAc = 20/1); ^1H NMR (400 MHz, CDCl_3) δ 7.86 (d, $J = 7.7$ Hz, 1H), 7.35–7.15 (m, 13H), 6.80 (s, 1H), 6.44–6.39 (m, 2H), 3.90 (ddd, $J = 10.4, 7.1, 3.0$ Hz, 1H), 3.30–3.17 (m, 2H), 2.60 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 161.2, 150.2, 142.9, 137.2, 137.1, 132.3, 131.6, 130.7, 129.6, 128.8, 128.7, 128.6, 127.6, 127.4, 126.9, 126.8, 126.3, 125.9, 125.0, 47.9, 32.4, 22.0; IR (neat) ν (cm^{-1}) 3059, 3025, 2923, 1679, 1599, 1492, 1451, 1242, 1108, 962, 729, 695, 525; HRMS exact mass calcd for ($\text{C}_{26}\text{H}_{23}\text{NO} + \text{H}$) requires m/z 366.1858, found m/z 366.1857.

(*E*)-2-(2-Chlorophenyl)-5-(2,4-diphenylbut-3-en-1-yl)oxazole (**3i**): yellow oil (62.5 mg, 81%, petroleum ether/EtOAc = 15/1); ^1H NMR (400 MHz, CDCl_3) δ 7.85 (dd, $J = 7.3, 2.2$ Hz, 1H), 7.48–7.41 (m, 1H), 7.36–7.14 (m, 12H), 6.84 (s, 1H), 6.42 (d, $J = 3.1$ Hz, 2H), 3.97–3.86 (m, 1H), 3.31–3.16 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 158.7, 151.2, 142.7, 137.1, 132.3, 132.1, 131.2, 130.73, 130.72, 130.67, 128.8, 128.6, 127.6, 127.5, 126.9, 126.8, 126.5, 126.3, 125.3, 47.9, 32.4; IR (neat) ν (cm^{-1}) 3057, 3025, 2920, 1599, 1570, 1492, 1451, 1431, 1239, 1130, 1038, 962, 826, 763, 731, 692, 654, 525;

HRMS exact mass calcd for ($\text{C}_{25}\text{H}_{20}\text{ClNO} + \text{H}$) requires m/z 386.1312, found m/z 386.1313.

(*E*)-5-(2,4-Diphenylbut-3-en-1-yl)-2-(*m*-tolyl)oxazole (**3j**): yellow oil (65.2 mg, 89% petroleum ether/EtOAc = 15/1); ^1H NMR (400 MHz, CDCl_3) δ 7.74 (d, $J = 9.2$ Hz, 2H), 7.40–6.93 (m, 12H), 6.74 (s, 1H), 6.50–6.12 (m, 2H), 3.91 (dd, $J = 6.8, 3.2$ Hz, 1H), 3.42–2.88 (m, 2H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 161.0, 150.6, 142.8, 138.5, 137.1, 132.2, 130.8, 130.7, 128.74, 128.65, 128.55, 127.6, 127.4, 126.9, 126.7, 126.3, 125.2, 123.2, 47.8, 32.5, 21.4; IR (neat) ν (cm^{-1}) 3057, 3025, 2918, 1599, 1548, 1492, 1451, 1264, 1195, 1118, 1069, 962, 792, 724, 690, 525; HRMS exact mass calcd for ($\text{C}_{25}\text{H}_{23}\text{NO} + \text{H}$) requires m/z 366.1858, found m/z 366.1860.

(*E*)-5-(2,4-Diphenylbut-3-en-1-yl)-2-(thiophen-2-yl)oxazole (**3k**): yellow oil (53.6 mg, 75%, petroleum ether/EtOAc = 15/1); ^1H NMR (400 MHz, CDCl_3) δ 7.57–7.51 (m, 1H), 7.40–7.15 (m, 11H), 7.06 (dd, $J = 4.8, 3.8$ Hz, 1H), 6.69 (s, 1H), 6.44–6.37 (m, 2H), 3.93–3.84 (m, 1H), 3.27–3.13 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.0, 150.2, 142.7, 137.1, 132.1, 130.7, 130.4, 128.8, 128.6, 127.9, 127.7, 127.6, 127.4, 127.1, 126.9, 126.3, 125.1, 47.6, 32.4; IR (neat) ν (cm^{-1}) 3059, 3023, 2906, 1596, 1492, 1448, 1424, 1113, 962, 850, 719, 692, 542, 488; HRMS exact mass calcd for ($\text{C}_{23}\text{H}_{19}\text{NOS} + \text{H}$) requires m/z 358.1266, found m/z 358.1269.

5-((*E*)-2,4-Diphenylbut-3-en-1-yl)-2-((*E*)-styryl)oxazole (**3l**): yellow oil (40.0 mg, 53%, petroleum ether/EtOAc = 15/1); ^1H NMR (400 MHz, CDCl_3) δ 7.48 (d, $J = 7.2$ Hz, 2H), 7.41–7.16 (m, 14H), 6.87 (d, $J = 16.4$ Hz, 1H), 6.71 (s, 1H), 6.42 (d, $J = 3.1$ Hz, 2H), 3.90 (ddd, $J = 10.4, 7.2, 3.0$ Hz, 1H), 3.28–3.12 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 160.7, 150.4, 142.8, 137.1, 135.7, 135.1, 132.2, 130.7, 129.0, 128.9, 128.8, 128.6, 127.6, 127.5, 127.1, 126.9, 126.3, 125.4, 114.2, 47.7, 32.5; IR (neat) ν (cm^{-1}) 3058, 3026, 2921, 1596, 1524, 1494, 1447, 1201, 1111, 1072, 1025, 960, 745, 689, 486; HRMS exact mass calcd for ($\text{C}_{27}\text{H}_{23}\text{NO} + \text{H}$) requires m/z 378.1858, found m/z 378.1857.

(*E*)-5-(2,4-Diphenylbut-3-en-1-yl)-2-methyl-4-phenyloxazole (**3m**): yellow oil (34.3 mg, 47%, petroleum ether/EtOAc = 15/1); ^1H NMR (400 MHz, CDCl_3) δ 7.54–7.45 (m, 2H), 7.36 (t, $J = 7.5$ Hz, 2H), 7.32–7.14 (m, 11H), 6.41–6.29 (m, 2H), 3.96 (dd, $J = 14.3, 7.1$ Hz, 1H), 3.32 (ddd, $J = 22.0, 14.9, 7.7$ Hz, 2H), 2.41 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.6, 145.2, 142.9, 137.2, 135.9, 132.3, 132.0, 130.5, 128.7, 128.6, 128.5, 127.6, 127.4, 127.3, 126.9, 126.8, 126.3, 47.7, 32.7, 13.9; IR (neat) ν (cm^{-1}) 3056, 3026, 2924, 1669, 1596, 1492, 1447, 1262, 1072, 962, 745, 693, 530; HRMS exact mass calcd for ($\text{C}_{26}\text{H}_{23}\text{NO} + \text{H}$) requires m/z 366.1858, found m/z 366.1852.

(*E*)-5-(2,4-Diphenylbut-3-en-1-yl)-2,4-diphenyloxazole (**3n**): yellow oil (60.0 mg, 86%, petroleum ether/EtOAc = 30/1); ^1H NMR (400 MHz, CDCl_3) δ 7.99 (dd, $J = 6.6, 3.0$ Hz, 2H), 7.58 (d, $J = 7.3$ Hz, 2H), 7.47–7.35 (m, 5H), 7.35–7.12 (m, 11H), 6.49–6.33 (m, 2H), 4.05 (q, $J = 7.3$ Hz, 1H), 3.44 (ddd, $J = 34.1, 14.9, 7.6$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.8, 145.7, 142.8, 137.5, 137.1, 132.3, 132.0, 130.6, 130.1, 128.7, 128.6, 128.5, 127.7, 127.62, 127.61, 127.4, 127.25, 127.24, 126.9, 126.28, 126.25, 47.9, 32.9; IR (neat) ν (cm^{-1}) 3058, 3024, 2921, 1667, 1596, 1555, 1491, 1445, 1069, 1006, 962, 774, 742, 715, 689, 484; HRMS exact mass calcd for ($\text{C}_{31}\text{H}_{25}\text{NO} + \text{H}$) requires m/z 428.2014, found m/z 428.2018.

(*E*)-5-(2,4-Bis(4-fluorophenyl)but-3-en-1-yl)-2-phenyloxazole (**3o**): yellow oil (52.1 mg, 68%, petroleum ether/EtOAc = 15/1); ^1H NMR (400 MHz, CDCl_3) δ 7.94 (dd, $J = 6.5, 3.0$ Hz, 2H), 7.47–7.36 (m, 3H), 7.32–7.15 (m, 4H), 7.06–6.90 (m, 4H), 6.75 (s, 1H), 6.31 (dt, $J = 15.9, 11.3$ Hz, 2H), 3.89 (q, $J = 7.3$ Hz, 1H), 3.20 (qd, $J = 15.2, 7.6$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 162.3 (d, $^1J_{\text{C-F}} = 245.0$ Hz), 161.7 (d, $^1J_{\text{C-F}} = 243.0$ Hz), 160.9, 150.3, 138.3 (d, $^4J_{\text{C-F}} = 3.0$ Hz), 133.1 (d, $^4J_{\text{C-F}} = 3.0$ Hz), 131.70, 131.68, 130.1, 129.6, 129.1 (d, $^3J_{\text{C-F}} = 8.0$ Hz), 128.8, 127.8 (d, $^3J_{\text{C-F}} = 8.0$ Hz), 127.6, 126.0, 125.3, 115.6 (d, $^2J_{\text{C-F}} = 21.0$ Hz), 115.5 (d, $^2J_{\text{C-F}} = 22.0$ Hz), 46.9, 32.5; IR (neat) ν (cm^{-1}) 3041, 2921, 1726, 1599, 1547, 1506, 1447, 1221, 1157, 1120, 1096, 967, 833, 774, 708, 691, 515; HRMS exact mass calcd for ($\text{C}_{25}\text{H}_{19}\text{F}_2\text{NO} + \text{H}$) requires m/z 388.1513, found m/z 388.1514.

(*E*)-5-(2,4-Bis(4-chlorophenyl)but-3-en-1-yl)-2-phenyloxazole (**3p**): yellow oil (41.9 mg, 50%, petroleum ether/EtOAc = 15/1); ¹H NMR (400 MHz, CDCl₃) δ 7.92 (dd, *J* = 6.6, 3.0 Hz, 2H), 7.46–7.38 (m, 3H), 7.30 (d, *J* = 8.4 Hz, 2H), 7.24–7.26 (m, 4H), 7.18 (d, *J* = 8.4 Hz, 2H), 6.75 (s, 1H), 6.35 (d, *J* = 2.9 Hz, 2H), 3.88 (dt, *J* = 10.3, 3.6 Hz, 1H), 3.20 (qd, *J* = 15.2, 7.5 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 161.0, 150.1, 140.9, 135.3, 133.2, 132.7, 132.3, 130.1, 129.9, 129.0, 128.9, 128.8, 128.7, 127.6, 127.5, 126.0, 125.3, 47.1, 32.3; IR (neat) ν (cm⁻¹) 3026, 2921, 1682, 1594, 1547, 1489, 1447, 1406, 1282, 1120, 1089, 1013, 964, 828, 808, 774, 708, 689, 501; HRMS exact mass calcd for (C₂₅H₁₉Cl₂NO + H) requires *m/z* 420.0922, found *m/z* 420.0919.

(*E*)-5-(2,4-Di-*p*-tolylbut-3-en-1-yl)-2-phenyloxazole (**3q**): yellow oil (43.9 mg, 58%, petroleum ether/EtOAc = 25/1); ¹H NMR (400 MHz, CDCl₃) δ 7.97–7.91 (m, 2H), 7.44–7.38 (m, 3H), 7.25–7.18 (m, 2H), 7.17–7.10 (m, 4H), 7.09–7.04 (m, 2H), 6.74 (s, 1H), 6.36 (d, *J* = 5.5 Hz, 2H), 3.86 (dd, *J* = 13.0, 7.4 Hz, 1H), 3.27–3.14 (m, 2H), 2.32 (s, 3H), 2.30 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 160.7, 150.9, 139.9, 137.1, 136.3, 134.4, 131.4, 130.3, 129.9, 129.4, 129.2, 128.7, 127.8, 127.5, 126.2, 126.0, 125.2, 47.2, 32.6, 21.2, 21.0; IR (neat) ν (cm⁻¹) 3019, 2921, 2855, 1594, 1547, 1514, 1484, 1450, 1262, 1118, 1064, 1020, 964, 798, 772, 711, 689, 503; HRMS exact mass calcd for (C₂₇H₂₃NO + H) requires *m/z* 380.2014, found *m/z* 380.2010.

(*E*)-2-Phenyl-5-(4-phenyl-2-(*p*-tolyl)but-3-en-1-yl)oxazole and (*E*)-2-phenyl-5-(2-phenyl-4-(*p*-tolyl)but-3-en-1-yl)oxazole (**3r/3r'**): yellow oil (54.9 mg, 75%, petroleum ether/EtOAc = 15/1); ¹H NMR (400 MHz, CDCl₃) δ 7.97–7.91 (m, 2H), 7.45–7.37 (m, 3H), 7.35–7.05 (m, 9H), 6.75 (s, 1H), 6.39 (dd, *J* = 13.6, 4.2 Hz, 2H), 3.93–3.84 (m, 1H), 3.29–3.15 (m, 2H), 2.32 (s, 1.77H), 2.31 (s, 1.22H); ¹³C NMR (100 MHz, CDCl₃) δ 160.8, 150.8, 142.9, 139.7, 137.2, 136.4, 134.3, 132.4, 131.2, 130.5, 130.4, 129.9, 129.4, 129.2, 128.7, 128.5, 127.8, 127.6, 127.5, 127.4, 126.8, 126.3, 126.2, 126.0, 125.2, 47.7, 47.3, 32.5, 21.2, 21.1; IR (neat) ν (cm⁻¹) 3024, 2921, 1682, 1596, 1547, 1513, 1484, 1447, 1250, 1120, 1064, 1023, 962, 813, 745, 708, 686, 501; HRMS exact mass calcd for (C₂₆H₂₃NO + H) requires *m/z* 366.1858, found *m/z* 366.1854.

2-Phenyl-5-(2,4,4-triphenylbut-3-en-1-yl)oxazole (**3s**): yellow oil (70.0 mg, 82%, petroleum ether/EtOAc = 20/1); ¹H NMR (400 MHz, CDCl₃) δ 7.88 (dd, *J* = 6.6, 2.9 Hz, 2H), 7.44–7.36 (m, 3H), 7.32 (t, *J* = 7.5 Hz, 2H), 7.27–7.11 (m, 11H), 6.96–6.87 (m, 2H), 6.78 (s, 1H), 6.27 (d, *J* = 10.5 Hz, 1H), 3.88 (dt, *J* = 10.4, 7.4 Hz, 1H), 3.11 (d, *J* = 7.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 160.9, 150.7, 143.8, 142.9, 142.1, 139.6, 130.6, 130.0, 129.6, 128.8, 128.7, 128.3, 128.1, 127.7, 127.4, 127.32, 127.26, 127.19, 126.7, 126.2, 125.2, 44.4, 33.6; IR (neat) ν (cm⁻¹) 3053, 3014, 2919, 1596, 1547, 1489, 1445, 1355, 1262, 1120, 1069, 1023, 977, 830, 759, 688, 630, 574, 532, 464; HRMS exact mass calcd for (C₃₁H₂₃NO + H) requires *m/z* 428.2014, found *m/z* 428.2015.

5-(4,4-Diphenyl-2-(*p*-tolyl)but-3-en-1-yl)-2-phenyloxazole (**3t**): yellow oil (46.9 mg, 53%, petroleum ether/EtOAc = 18/1); ¹H NMR (400 MHz, CDCl₃) δ 7.88 (dd, *J* = 6.4, 3.0 Hz, 2H), 7.44–7.37 (m, 3H), 7.28–7.10 (m, 12H), 6.95–6.88 (m, 2H), 6.78 (s, 1H), 6.25 (d, *J* = 10.5 Hz, 1H), 3.85 (dt, *J* = 10.5, 7.4 Hz, 1H), 3.09 (d, *J* = 7.4 Hz, 2H), 2.33 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 160.8, 150.8, 142.6, 142.1, 140.8, 139.6, 136.2, 130.8, 129.9, 129.6, 129.5, 128.6, 128.2, 128.1, 127.7, 127.4, 127.2, 127.11, 127.09, 126.1, 125.1, 43.9, 33.7, 21.1; IR (neat) ν (cm⁻¹) 3055, 3021, 2921, 1596, 1545, 1513, 1486, 1443, 1355, 1120, 1072, 1025, 979, 815, 759, 691, 623, 593, 528; HRMS exact mass calcd for (C₃₂H₂₇NO + H) requires *m/z* 442.2171, found *m/z* 442.2158.

5-(2-(4-Chlorophenyl)-4,4-diphenylbut-3-en-1-yl)-2-phenyloxazole (**3u**): yellow oil (80.4 mg, 87%, petroleum ether/EtOAc = 15/1); ¹H NMR (400 MHz, CDCl₃) δ 7.87 (dd, *J* = 6.6, 2.9 Hz, 2H), 7.44–7.35 (m, 3H), 7.32–7.10 (m, 12H), 6.94–6.86 (m, 2H), 6.78 (s, 1H), 6.22 (d, *J* = 10.4 Hz, 1H), 3.85 (dt, *J* = 10.2, 7.4 Hz, 1H), 3.08 (d, *J* = 7.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 161.0, 150.3, 143.4, 142.3, 141.9, 139.5, 132.4, 130.0, 129.9, 129.5, 128.9, 128.7, 128.6, 128.3, 128.2, 127.6, 127.5, 127.33, 127.31, 126.1, 125.3, 43.8, 33.6; IR (neat) ν (cm⁻¹) 3055, 3021, 2921, 1594, 1547, 1489, 1445, 1357,

1262, 1118, 1089, 1011, 979, 825, 759, 691, 585, 532; HRMS exact mass calcd for (C₃₁H₂₄ClNO + H) requires *m/z* 462.1625, found *m/z* 462.1632.

5-(2-(4-Methoxyphenyl)-4,4-diphenylbut-3-en-1-yl)-2-phenyloxazole (**3v**): yellow oil (37.2 mg, 41%, petroleum ether/EtOAc = 12/1); ¹H NMR (400 MHz, CDCl₃) δ 7.91–7.85 (m, 2H), 7.44–7.37 (m, 3H), 7.27–7.13 (m, 10H), 6.92 (dd, *J* = 7.6, 1.6 Hz, 2H), 6.87 (d, *J* = 8.7 Hz, 2H), 6.78 (s, 1H), 6.24 (d, *J* = 10.5 Hz, 1H), 3.84 (dt, *J* = 10.6, 7.5 Hz, 1H), 3.79 (s, 3H), 3.09 (d, *J* = 7.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 160.8, 158.3, 150.8, 142.5, 142.1, 139.6, 135.9, 130.9, 129.9, 129.6, 128.6, 128.22, 128.16, 128.10, 127.7, 127.34, 127.25, 127.1, 126.1, 125.1, 114.2, 55.3, 43.5, 33.7; IR (neat) ν (cm⁻¹) 3055, 3021, 2924, 2833, 1595, 1547, 1508, 1486, 1443, 1357, 1245, 1174, 1120, 1072, 1030, 977, 828, 762, 691, 625, 593, 542; HRMS exact mass calcd for (C₃₂H₂₇NO₂ + H) requires *m/z* 458.2120, found *m/z* 458.2119.

5-(2-(Naphthalen-1-yl)-4,4-diphenylbut-3-en-1-yl)-2-phenyloxazole (**3w**): yellow solid (50.8 mg, 53%, petroleum ether/EtOAc = 15/1); mp 67–69 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.88 (dd, *J* = 11.5, 5.6 Hz, 3H), 7.74 (dd, *J* = 15.2, 8.3 Hz, 2H), 7.58 (d, *J* = 7.1 Hz, 1H), 7.51–7.34 (m, 6H), 7.29–7.10 (m, 8H), 6.87 (d, *J* = 7.2 Hz, 2H), 6.81 (s, 1H), 6.51 (d, *J* = 10.2 Hz, 1H), 4.75 (td, *J* = 9.6, 5.0 Hz, 1H), 3.22 (ddd, *J* = 24.5, 15.3, 7.0 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 160.9, 150.8, 143.2, 142.3, 140.3, 139.5, 134.2, 130.8, 130.6, 130.0, 129.7, 129.1, 128.7, 128.22, 128.15, 127.7, 127.6, 127.4, 127.31, 127.26, 126.14, 126.08, 125.7, 125.6, 125.2, 124.3, 123.0, 39.2, 34.0; IR (neat) ν (cm⁻¹) 3048, 2953, 2924, 2853, 1596, 1545, 1482, 1445, 1264, 1118, 1069, 1023, 977, 876, 825, 796, 767, 737, 701, 686, 642, 564; HRMS exact mass calcd for (C₃₅H₂₇NO + H) requires *m/z* 478.2171, found *m/z* 478.2174.

General Procedure for the Synthesis of Compounds 4. To a solution of Yb(OTf)₃ (0.02 mmol) and **3** (0.2 mmol) in CH₂Cl₂ (1.5 mL) was slowly added a solution of DDQ (0.2 mmol) in CH₂Cl₂ (1.5 mL). The reaction mixture was stirred at room temperature until the reaction was completed (monitored by TLC). After removal of the solvent under reduced pressure, the residue was purified through column chromatography.

5-((1*Z*,3*E*)-2,4-Diphenylbuta-1,3-dien-1-yl)-2-phenyloxazole (**4a**): pale yellow solid (30.0 mg, 43%, petroleum ether/EtOAc = 40/1); mp 105–107 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.10 (dd, *J* = 7.3, 2.0 Hz, 2H), 7.95 (d, *J* = 16.1 Hz, 1H), 7.56–7.28 (m, 14H), 6.63 (d, *J* = 16.1 Hz, 1H), 6.38 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 161.2, 150.4, 141.2, 141.0, 137.3, 135.4, 130.5, 129.2, 128.93, 128.88, 128.82, 128.4, 128.2, 128.0, 127.4, 126.9, 126.8, 126.4, 114.5; IR (neat) ν (cm⁻¹) 3060, 3021, 2955, 2921, 2850, 1726, 1682, 1472, 1447, 1257, 1130, 1069, 1023, 979, 967, 862, 772, 745, 686, 523, 490; HRMS exact mass calcd for (C₂₅H₁₉NO + H) requires *m/z* 350.1545, found *m/z* 350.1564.

5-((1*Z*,3*E*)-2,4-Diphenylbuta-1,3-dien-1-yl)-2-(4-methoxyphenyl)oxazole (**4c**): pale yellow solid (38.1 mg, 51%, petroleum ether/EtOAc = 20/1); mp 127–129 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, *J* = 8.8 Hz, 2H), 7.94 (d, *J* = 16.1 Hz, 1H), 7.54–7.24 (m, 11H), 7.00 (d, *J* = 8.8 Hz, 2H), 6.62 (d, *J* = 16.1 Hz, 1H), 6.37 (s, 1H), 3.88 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 161.5, 161.4, 149.9, 141.1, 140.6, 137.4, 135.1, 129.2, 128.83, 128.80, 128.4, 128.11, 128.10, 127.9, 126.9, 120.2, 116.4, 114.7, 114.4, 55.4; IR (neat) ν (cm⁻¹) 3077, 2953, 2921, 2850, 1606, 1513, 1482, 1369, 1299, 1248, 1167, 1140, 1106, 1020, 972, 874, 833, 750, 701, 689, 613, 586, 520, 484; HRMS exact mass calcd for (C₂₆H₂₁NO₂ + H) requires *m/z* 380.1651, found *m/z* 380.1648.

5-((1*Z*,3*E*)-2,4-Diphenylbuta-1,3-dien-1-yl)-2-(4-(trifluoromethyl)phenyl)oxazole (**4f**): pale yellow solid (35.1 mg, 42%, petroleum ether/EtOAc = 30/1); mp 113–115 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, *J* = 8.2 Hz, 2H), 7.87 (d, *J* = 16.1 Hz, 1H), 7.73 (d, *J* = 8.3 Hz, 2H), 7.53–7.26 (m, 11H), 6.66 (d, *J* = 16.1 Hz, 1H), 6.40 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 159.7, 151.2, 142.3, 140.8, 137.1, 136.1, 130.5, 129.13, 129.11, 128.97, 128.87, 128.85, 128.42, 128.40, 128.2, 126.9, 126.5, 125.96, 125.92, 114.1; IR (neat) ν (cm⁻¹) 2960, 2921, 2853, 1689, 1494, 1457, 1374, 1321, 1257, 1164, 1059,

1016, 795, 750, 691,669, 589, 523, 476; HRMS exact mass calcd for (C₂₆H₁₈F₃NO + H) requires *m/z* 418.1419, found *m/z* 418.1407.

3,3-Diphenyl-1-(*p*-tolyl)prop-2-en-1-ol (2t): ¹H NMR (400 MHz, CDCl₃) δ 7.44–7.31 (m, 3H), 7.30–7.19 (m, 9H), 7.15 (d, *J* = 7.8 Hz, 2H), 6.29 (d, *J* = 9.4 Hz, 1H), 5.22 (d, *J* = 9.4 Hz, 1H), 2.34 (s, 3H), 1.94 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 143.3, 141.7, 140.6, 139.2, 137.4, 130.3, 129.9, 129.4, 128.4, 128.2, 127.73, 127.68, 127.65, 126.3, 71.6, 21.2; HRMS exact mass calcd for (C₂₂H₂₀O–OH) requires *m/z* 283.1481, found *m/z* 283.1495.

1-(4-Methoxyphenyl)-3,3-diphenylprop-2-en-1-ol (2v): ¹H NMR (400 MHz, CDCl₃) δ 7.42–7.12 (m, 12H), 6.88 (d, *J* = 8.6 Hz, 2H), 6.30 (d, *J* = 9.3 Hz, 1H), 5.21 (d, *J* = 9.3 Hz, 1H), 3.79 (s, 3H), 1.94 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 158.9, 143.0, 141.7, 139.3, 133.9, 129.9, 128.4, 128.11, 128.05, 127.97, 127.6, 127.5, 113.9, 113.7, 74.8, 55.3; HRMS exact mass calcd for (C₂₂H₂₀O₂–OH) requires *m/z* 299.1430, found *m/z* 299.1447.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b02382.

Synthesis, HPLC and X-ray crystal data, luminescence images, and ¹H and ¹³C NMR and HRMS spectra (PDF) X-ray crystal data (CIF)

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail: xuzh@sdu.edu.cn.

*E-mail: jwwang@sdu.edu.cn.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We are grateful for financial support from the Natural Science Foundation of China and Shandong province (No. 21572118 and JQ201505), China Postdoctoral Science Foundation, and the fundamental research & subject construction funds of Shandong University (No. 2014JC008 and 104.205.2.S).

■ REFERENCES

- (1) (a) Turchi, I. J.; Dewar, M. J. S. *Chem. Rev.* **1975**, *75*, 389. (b) Jin, Z. *Nat. Prod. Rep.* **2003**, *20*, 584. (c) Jin, Z. *Nat. Prod. Rep.* **2009**, *26*, 382. (d) Dalvie, D. K.; Kalgutkar, A. S.; Khojasteh-Bakht, S. C.; Obach, R. S.; O'Donnell, J. P. *Chem. Res. Toxicol.* **2002**, *15*, 269. (e) Mulder, R. J.; Shafer, C. M.; Molinski, T. F. *J. Org. Chem.* **1999**, *64*, 4995. (f) Pettit, G. R.; Hogan, F.; Xu, J. P.; Tan, R.; Nogawa, T.; Cichacz, Z.; Pettit, R. K.; Du, J.; Ye, Q. H.; Cragg, G. M.; Herald, C. L.; Hoard, M. S.; Goswami, A.; Searcy, J.; Tackett, L.; Doubek, D. L.; Williams, L.; Hooper, J. N. A.; Schmidt, J. M.; Chapuis, J. C.; Tackett, D. N.; Craciunescu, F. J. *Nat. Prod.* **2008**, *71*, 438.
- (2) For example: Gissibl, A.; Finn, M. G.; Reiser, O. *Org. Lett.* **2005**, *7*, 2325.
- (3) (a) Hu, Y.; Xin, X.; Wan, B. *Tetrahedron Lett.* **2015**, *56*, 32. (b) Hu, Y.; Yi, R.; Wang, C.; Xin, X.; Wu, F.; Wan, B. *J. Org. Chem.* **2014**, *79*, 3052. (c) Yu, X.; Xin, X.; Wan, B.; Li, X. *J. Org. Chem.* **2013**, *78*, 4895. (d) Hashmi, A. S. K.; Blanco Jaimes, M. C.; Schuster, A. M.; Rominger, F. *J. Org. Chem.* **2012**, *77*, 6394. (e) Senadi, G. C.; Hu, W. P.; Hsiao, J. S.; Vandavasi, J. K.; Chen, C. Y.; Wang, J. *J. Org. Lett.* **2012**, *14*, 4478. (f) Egorova, O. A.; Seo, H.; Kim, Y.; Moon, D.; Rhee, Y. M.; Ahn, K. H. *Angew. Chem., Int. Ed.* **2011**, *50*, 11446. (g) Saito, A.; Iimura, K.; Hanzawa, Y. *Tetrahedron Lett.* **2010**, *51*, 1471. (h) Hashmi, A. S. K.; Schuster, A. M.; Schmuck, M.; Rominger, F. *Eur. J. Org. Chem.* **2011**, *2011*, 4595.
- (4) Arcadi, A.; Cacchi, S.; Cascia, L.; Fabrizi, G.; Marinelli, F. *Org. Lett.* **2001**, *3*, 2501.

(5) Weyrauch, J. P.; Hashmi, A. S. K.; Schuster, A.; Hengst, T.; Schetter, S.; Littmann, A.; Rudolph, M.; Hamzic, M.; Visus, J.; Rominger, F.; Frey, W.; Bats, J. W. *Chem. - Eur. J.* **2010**, *16*, 956.

(6) Peng, H.; Akhmedov, N. G.; Liang, Y.; Jiao, N.; Shi, X. *J. Am. Chem. Soc.* **2015**, *137*, 8912.

(7) (a) Wang, X.; Dong, S.; Yao, Z.; Feng, L.; Daka, P.; Wang, H.; Xu, Z. *Org. Lett.* **2014**, *16*, 22. (b) Wang, X.; Yao, Z.; Dong, S.; Wei, F.; Wang, H.; Xu, Z. *Org. Lett.* **2013**, *15*, 2234. (c) Zhang, S.; Xu, Z.; Jia, J.; Tung, C.-H.; Xu, Z. *Chem. Commun.* **2014**, *50*, 12084. (d) Zhang, S.; Chen, Y.; Wang, J.; Pan, Y.; Xu, Z.; Tung, C.-H. *Org. Chem. Front.* **2015**, *2*, 578.

(8) (a) Trost, B. M.; Van Vranken, D. L. *Chem. Rev.* **1996**, *96*, 395. (b) Marshall, J. A. *Chem. Rev.* **2000**, *100*, 3163. (c) Braun, M.; Meier, T. *Angew. Chem., Int. Ed.* **2006**, *45*, 6952. (d) Zheng, C.; Zhuo, C. X.; You, S.-L. *J. Am. Chem. Soc.* **2014**, *136*, 16251. (e) Chen, W. Y.; Chen, M.; Hartwig, J. F. *J. Am. Chem. Soc.* **2014**, *136*, 15825. (f) Qu, J.; Roßberg, L.; Helmchen, G. *J. Am. Chem. Soc.* **2014**, *136*, 1272. (g) Hamilton, J. Y.; Hauser, N.; Sarlah, D.; Carreira, E. M. *Angew. Chem., Int. Ed.* **2014**, *53*, 10759. (h) Lei, B. L.; Ding, C. H.; Yang, X. F.; Wan, X. L.; Hou, X.-L. *J. Am. Chem. Soc.* **2009**, *131*, 18250.

(9) For a review, see: (a) Sarkar, A.; Santra, S.; Kundu, S. K.; Ghosal, N. C.; Hajra, A.; Majee, A. *Synthesis* **2015**, *47*, 1379. For recent examples, see: (b) Jadhav, A. M.; Pagar, V. V.; Huple, D. B.; Liu, R. S. *Angew. Chem., Int. Ed.* **2015**, *54*, 3812. (c) Li, L.; Zhou, B.; Wang, Y.; Shu, C.; Pan, Y.-F.; Lu, X.; Ye, L.-W. *Angew. Chem., Int. Ed.* **2015**, *54*, 8245. (d) González, M. J.; González, J.; López, L. A.; Vicente, R. *Angew. Chem., Int. Ed.*, **2015**, *54*, DOI: 10.1002/anie.201505954. (e) Cheng, C.; Liu, S.; Zhu, G. *Org. Lett.* **2015**, *17*, 1581. (f) González, M. J.; López, L. A.; Vicente, R. *Org. Lett.* **2014**, *16*, 5780. (g) Song, B.; Li, L.-H.; Song, X.-R.; Qiu, Y.-F.; Zhong, M.-J.; Zhou, P.-X.; Liang, Y.-M. *Chem. - Eur. J.* **2014**, *20*, 5910.

(10) (a) Bandini, M. *Angew. Chem., Int. Ed.* **2011**, *50*, 994. (b) Lumbroso, A.; Cooke, M. L.; Breit, B. *Angew. Chem., Int. Ed.* **2013**, *52*, 1890. (c) Sundararaju, B.; Achard, M.; Bruneau, C. *Chem. Soc. Rev.* **2012**, *41*, 4467. (d) Krautwald, S.; Schafroth, M. A.; Sarlah, D.; Carreira, E. M. *J. Am. Chem. Soc.* **2014**, *136*, 3020. (e) Krautwald, S.; Sarlah, D.; Schafroth, M. A.; Carreira, E. M. *Science* **2013**, *340*, 1065. (f) Zhang, X.; Yang, Z.-P.; Liu, C.; You, S.-L. *Chem. Sci.* **2013**, *4*, 3239.

(11) For a review on dehydrative coupling reactions, see: Kumar, R.; Van der Eycken, E. V. *Chem. Soc. Rev.* **2013**, *42*, 1121.

(12) (a) Stopka, T.; Niggemann, M. *Org. Lett.* **2015**, *17*, 1437. (b) Tan, W.; Du, B.; Li, X.; Zhu, X.; Shi, F.; Tu, S.-J. *J. Org. Chem.* **2014**, *79*, 4635. (c) Zhang, T.; Qiao, Z.; Wang, Y.; Zhong, N.; Liu, L.; Wang, D.; Chen, Y.-J. *Chem. Commun.* **2013**, *49*, 1636. (d) Xiao, J. *Org. Lett.* **2012**, *14*, 1716. (e) Guo, C.; Song, J.; Huang, J.; Chen, P.; Luo, S.; Gong, L.-Z. *Angew. Chem., Int. Ed.* **2012**, *51*, 1046. (f) Capdevila, M. G.; Benfatti, F.; Zoli, L.; Stenta, M.; Cozzi, P. G. *Chem. - Eur. J.* **2010**, *16*, 11237. (g) Cozzi, P. G.; Benfatti, F.; Zoli, L. *Angew. Chem., Int. Ed.* **2009**, *48*, 1313.

(13) Guo, C.; Song, J.; Luo, S.; Gong, L.-Z. *Angew. Chem., Int. Ed.* **2010**, *49*, 5558.

(14) CCDC 1421020 (4f) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

(15) For reviews on AIE effect, see: (a) Hong, Y.; Lam, J. W. Y.; Tang, B. Z. *Chem. Commun.* **2009**, 4332. (b) Hong, Y.; Lam, J. W. Y.; Tang, B. Z. *Chem. Soc. Rev.* **2011**, *40*, 5361. For the applications of AIE active materials, see: (c) Wang, H.; Liu, J.; Han, A.; Xiao, N.; Xue, Z.; Wang, G.; Long, J.; Kong, D.; Liu, B.; Yang, Z.; Ding, D. *ACS Nano* **2014**, *8*, 1475. (d) Gao, M.; Sim, C. K.; Leung, C. W. T.; Hu, Q.; Feng, G.; Xu, F.; Tang, B. Z.; Liu, B. *Chem. Commun.* **2014**, *50*, 8312. (e) Song, C.; Sun, Y.; Wang, J.; Chen, H.; Yao, J.; Tung, C.-H.; Xu, Z. *Org. Chem. Front.* **2015**, *2*, 1366.

(16) (a) Xu, C.; Xu, M.; Yang, L.; Li, C. *J. Org. Chem.* **2012**, *77*, 3010. (b) Teral, Y.; Roubaud, G.; Aubert, C.; Faure, R.; Campredon, M. *Aust. J. Chem.* **2005**, *58*, 517.